Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 6848902, 17 pages
http://dx.doi.org/10.1155/2016/6848902
Review Article

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

Department of Hematology, The First Hospital, China Medical University, Shenyang 110001, China

Received 7 September 2015; Revised 15 December 2015; Accepted 22 December 2015

Academic Editor: Raj P. Kandpal

Copyright © 2016 Xiaoxue Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Zou, Z. Sheng, H. Lu, and J. Yu, “Continuous treatment with new agents for newly diagnosed multiple myeloma,” Anti-Cancer Drugs, vol. 24, no. 5, pp. 527–533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Kyle, M. A. Gertz, T. E. Witzig et al., “Review of 1027 patients with newly diagnosed multiple myeloma,” Mayo Clinic Proceedings, vol. 78, no. 1, pp. 21–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. B. A. Kohler, E. Ward, B. J. McCarthy et al., “Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system,” Journal of the National Cancer Institute, vol. 103, no. 9, pp. 714–736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. G. Schaar, S. le Cessie, S. Snijder et al., “Long-term follow-up of a population based cohort with monoclonal proteinaemia,” British Journal of Haematology, vol. 144, no. 2, pp. 176–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Landgren, S. V. Rajkumar, R. M. Pfeiffer et al., “Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women,” Blood, vol. 116, no. 7, pp. 1056–1059, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. K. Kumar, S. V. Rajkumar, A. Dispenzieri et al., “Improved survival in multiple myeloma and the impact of novel therapies,” Blood, vol. 111, no. 5, pp. 2516–2520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Blade, D. Samson, D. Reece et al., “Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation,” British Journal of Haematology, vol. 102, no. 5, pp. 1115–1123, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. J. F. Tierney, L. A. Stewart, D. Ghersi, S. Burdett, and M. R. Sydes, “Practical methods for incorporating summary time-to-event data into meta-analysis,” Trials, vol. 8, article 16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. F. San Miguel, R. Schlag, N. K. Khuageva et al., “Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma,” The New England Journal of Medicine, vol. 359, no. 9, pp. 906–917, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M.-V. Mateos, P. G. Richardson, R. Schlag et al., “Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2259–2266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. F. San Miguel, R. Schlag, N. K. Khuageva et al., “Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 448–455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-L. Harousseau, M. Attal, H. Avet-Loiseau et al., “Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial,” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4621–4629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Cavo, P. Tacchetti, F. Patriarca et al., “Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study,” The Lancet, vol. 376, no. 9758, pp. 2075–2085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Cavo, L. Pantani, M. T. Petrucci et al., “Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma,” Blood, vol. 120, no. 1, pp. 9–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Rosiñol, A. Oriol, A. I. Teruel et al., “Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study,” Blood, vol. 120, no. 8, pp. 1589–1596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Sonneveld, I. G. H. Schmidt-Wolf, B. van der Holt et al., “Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial,” Journal of Clinical Oncology, vol. 30, no. 24, pp. 2946–2955, 2012. View at Publisher · View at Google Scholar
  18. S. V. Rajkumar, L. Rosiñol, M. Hussein et al., “Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2171–2177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Hulin, T. Facon, P. Rodon et al., “Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial,” Journal of Clinical Oncology, vol. 27, no. 22, pp. 3664–3670, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Wijermans, M. Schaafsma, F. Termorshuizen et al., “Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3160–3166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Palumbo, S. Bringhen, T. Caravita et al., “Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial,” The Lancet, vol. 367, no. 9513, pp. 825–831, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Palumbo, S. Bringhen, A. M. Liberati et al., “Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial,” Blood, vol. 112, no. 8, pp. 3107–3114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Facon, J. Y. Mary, C. Hulin et al., “Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial,” The Lancet, vol. 370, no. 9594, pp. 1209–1218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Waage, P. Gimsing, P. Fayers et al., “Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma,” Blood, vol. 116, no. 9, pp. 1405–1412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Barlogie, M. Pineda-Roman, F. van Rhee et al., “Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities,” Blood, vol. 112, no. 8, pp. 3115–3121, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Barlogie, G. Tricot, E. Anaissie et al., “Thalidomide and hematopoietic-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 354, no. 10, pp. 1021–1030, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. H. M. Lokhorst, I. Schmidt-Wolf, P. Sonneveld et al., “Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma,” Haematologica, vol. 93, no. 1, pp. 124–127, 2008. View at Publisher · View at Google Scholar
  28. H. M. Lokhorst, B. van der Holt, S. Zweegman et al., “A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma,” Blood, vol. 115, no. 6, pp. 1113–1120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Beksac, R. Haznedar, T. Firatli-Tuglular et al., “Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group,” European Journal of Haematology, vol. 86, no. 1, pp. 16–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Sacchi, R. Marcheselli, A. Lazzaro et al., “A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant,” Leukemia & Lymphoma, vol. 52, no. 10, pp. 1942–1948, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Zonder, J. Crowley, M. A. Hussein et al., “Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232),” Blood, vol. 116, no. 26, pp. 5838–5841, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Palumbo, R. Hajek, M. Delforge et al., “Continuous lenalidomide treatment for newly diagnosed multiple myeloma,” The New England Journal of Medicine, vol. 366, no. 19, pp. 1759–1769, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Andhavarapu and V. Roy, “Immunomodulatory drugs in multiple myeloma,” Expert Review of Hematology, vol. 6, no. 1, pp. 69–82, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Sonneveld, H. Goldschmidt, L. Rosiñol et al., “Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials,” Journal of Clinical Oncology, vol. 31, no. 26, pp. 3279–3287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. A. K. Nooka, J. L. Kaufman, M. Behera et al., “Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials,” Cancer, vol. 119, no. 23, pp. 4119–4128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Zeng, J. Lin, and J. Chen, “Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials,” Annals of Hematology, vol. 92, no. 7, pp. 935–943, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Yang, R.-L. Yu, X.-H. Chi, and X.-C. Lu, “Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials,” PLoS ONE, vol. 8, no. 5, Article ID e64354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Zou, M. Lin, Z. Sheng, and S. Niu, “Bortezomib and lenalidomide as front-line therapy for multiple myeloma,” Leukemia & Lymphoma, vol. 55, no. 9, pp. 2024–2031, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. P. M. Fayers, A. Palumbo, C. Hulin et al., “Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials,” Blood, vol. 118, no. 5, pp. 1239–1247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Tacchetti, C. Terragna, M. Galli et al., “Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study,” American Journal of Hematology, vol. 89, no. 12, pp. 1085–1091, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Bagratuni, E. Kastritis, M. Politou et al., “Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens,” American Journal of Hematology, vol. 88, no. 9, pp. 765–770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Palumbo, S. Bringhen, S. K. Kumar et al., “Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data,” The Lancet Oncology, vol. 15, no. 3, pp. 333–342, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. P. L. McCarthy, K. Owzar, C. C. Hofmeister et al., “Lenalidomide after stem-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 366, no. 19, pp. 1770–1781, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Attal, V. Lauwers-Cances, G. Marit et al., “Lenalidomide maintenance after stem-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 366, no. 19, pp. 1782–1791, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Benboubker, M. A. Dimopoulos, A. Dispenzieri et al., “Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma,” The New England Journal of Medicine, vol. 371, no. 10, pp. 906–917, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Gay, S. R. Hayman, M. Q. Lacy et al., “Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients,” Blood, vol. 115, no. 7, pp. 1343–1350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. K. Stewart, S. J. Jacobus, R. Fonseca et al., “E1A06: a phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM),” in Proceedings of the ASCO Annual Meeting, Chicago, Ill, USA, May 2014.
  48. S. Ozaki, T. Harada, T. Saitoh et al., “Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network,” Acta Haematologica, vol. 132, no. 2, pp. 211–219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Cavo, S. V. Rajkumar, A. Palumbo et al., “International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation,” Blood, vol. 117, no. 23, pp. 6063–6073, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. A. K. Stewart, S. Trudel, N. J. Bahlis et al., “A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial,” Blood, vol. 121, no. 9, pp. 1517–1523, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Palumbo, S. Bringhen, A. Larocca et al., “Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival,” Journal of Clinical Oncology, vol. 32, no. 7, pp. 634–640, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Yaqub, G. Ballester, and O. Ballester, “Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials,” Cancer Investigation, vol. 31, no. 8, pp. 529–537, 2013. View at Publisher · View at Google Scholar · View at Scopus